{"groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"FG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"FG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"10"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"End of survival follow-up not available"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"14"}],"type":"Data collection finished"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"83"}],"type":"Did not enter Survival Follow up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"194"},{"groupId":"FG001","numSubjects":"379"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"193"},{"groupId":"FG001","numSubjects":"374"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"145"},{"groupId":"FG001","numSubjects":"291"}],"type":"Entered Survival FU"},{"achievements":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"258"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"121"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Overall, 843 subjects were screened, of them 270 subjects were screening failures. 573 subjects were randomized and assigned to treatment; of them 6 subjects never received treatment. 436 Entered survival Follow-up and 4 End of survival follow-up data not available.","recruitmentDetails":"The study was conducted between 14 May 2013 (first subject first visit), 29 February 2016 (primary completion date) and 05-July-2019 (Last Patient Last Visit =End of study)."}